TRIB (Trinity Biotech) Total Receivables: $10.28 Mil (As of Dec. 2025)


TRIB Trinity Biotech PLC TRIB
26 GF Score
Price $0.38
GF Value $0.73
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Trinity Biotech Total Receivables?

Trinity Biotech TRIB -7.97% 26 Total Receivables is $10.28 Mil as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 26/100 and a GF Value™ of $0.73 (Possible Value Trap). The stock has 6 warning signs investors should review.

Trinity Biotech's Total Receivables for the quarter that ended in Dec. 2025 was $10.28 Mil.

Trinity Biotech Total Receivables Related Terms

Trinity Biotech Total Receivables Historical Data

* Premium members only.

The historical data trend for Trinity Biotech's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech Total Receivables Chart

Trinity Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.71 15.65 13.38 14.60 10.28

Trinity Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.38 17.71 14.60 11.32 10.28
TRIB
26GF Score
Trinity Biotech PLC TRIB
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Trinity Biotech Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $10.28 Mil mean?
Trinity Biotech (TRIB) has a Total Receivables of $10.28 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Trinity Biotech and its competitors.
Is Trinity Biotech's Total Receivables too high?
Trinity Biotech's current Total Receivables is $10.28 Mil. Overall, Trinity Biotech has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Total Receivables compare to AIDX and NVNO?
Trinity Biotech's Total Receivables of $10.28 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Trinity Biotech and its competitors. Trinity Biotech's current Total Receivables is $10.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.38 — trading 47.3% below its estimated fair value. The current Total Receivables is $10.28 Mil. Trinity Biotech's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current Total Receivables is $10.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $0.38 is trading 47.3% below its estimated GF Value™ of $0.73. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

  • Total Receivables: $10.28 Mil
  • GF Value™: $0.73 vs. price of $0.38 (47.3% below fair value)
  • GF Score™: 26/100 with 6 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Trinity Biotech Business Description

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
26GF Score

Get the complete analysis for TRIB

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price
$0.73
GF Value